文献速递淋巴瘤

SWOG S0016研究中滤泡性淋巴瘤患者预后相关基因组改变

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
PubMed 文献 · Blood · 2018-11-16

在SWOG S0016研究的255例滤泡性淋巴瘤患者中,用染色体基因组微阵列检测诊断时的拷贝数异常和拷贝中性杂合性缺失,发现基因组复杂度增加与不良预后相关,2p获得、CDKN2A/B缺失、CREBBP缺失和TP53缺失等与早期进展、无进展生存或总生存相关。

要点

  • 基因组复杂度(异常判读总数)增加与滤泡性淋巴瘤不良结局相关。
  • 2p获得预测无进展生存和总生存,CDKN2A/B缺失与更差无进展生存相关。
  • CREBBP和TP53缺失预测更差总生存,部分结果在m7-FLIPI独立队列中验证。

核心结论

  • 诊断时用染色体基因组微阵列检测基因组异常可独立于已知临床参数改善风险分层,并为未来合理靶向治疗提供框架。

研究设计与样本

  • 利用SWOG S0016研究前瞻性收集的255例滤泡性淋巴瘤患者诊断时标本,用染色体基因组微阵列检测拷贝数异常和拷贝中性杂合性缺失。

主要发现

  • 早期进展与2p获得相关(P=0.007;OR=2.55[1.29,5.03]),也与2p拷贝中性杂合性缺失相关(P=0.005;OR=10.9[2.08,57.2])。
  • 2p获得且特异累及VRK2和FANCL预测无进展生存(P=0.01;HR=1.80[1.14,2.68])和总生存(P=0.005;HR=2.40[1.30,4.40])。
  • CDKN2A/B(9p)缺失与更差无进展生存相关(P=0.004;HR=3.50[1.51,8.28])。
  • CREBBP(16p)缺失(P<0.001;HR=6.70[2.52,17.58])和TP53(17p)缺失(P<0.001;HR=3.90[1.85,8.31])预测更差总生存。
  • 在m7-FLIPI研究独立队列中进一步验证了异常计数、TP53和CDKN2A/B缺失的预后意义。

关键数值与推荐

  • 早期进展定义为注册后2年内进展或死亡。
  • 2p获得:早期进展OR=2.55[1.29,5.03],P=0.007;2p拷贝中性杂合性缺失:OR=10.9[2.08,57.2],P=0.005。
  • 2p获得且累及VRK2和FANCL:无进展生存HR=1.80[1.14,2.68],P=0.01;总生存HR=2.40[1.30,4.40],P=0.005。
  • CDKN2A/B(9p)缺失:无进展生存HR=3.50[1.51,8.28],P=0.004。
  • CREBBP(16p)缺失:总生存HR=6.70[2.52,17.58],P<0.001;TP53(17p)缺失:总生存HR=3.90[1.85,8.31],P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P < .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P < .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Qu X, Li H, Braziel RM, et al. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. Blood. 2018. PMID: 30446494. doi:10.1182/blood-2018-07-865428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。